SEC Comment Letter 0000000000-24-013069 to ARS Pharmaceuticals, Inc. (SPRY) (CIK 0001671858) (SPRY)
ARS Pharmaceuticals, Inc. (SPRY) (CIK 0001671858)
Date: Nov. 25, 2024 · CIK: 0001671858 · Accession: 0000000000-24-013069
AI Filing Summary & Sentiment
File numbers found in text: 001-39756
Letter
November 25, 2024 Kathleen Scott Chief Financial Officer ARS Pharmaceuticals, Inc. 11682 El Camino Real Suite 120 San Diego, CA 92130 Re:ARS Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2023 File No. 001-39756 Dear Kathleen Scott: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences
Show Raw Text
November 25, 2024
Kathleen Scott
Chief Financial Officer
ARS Pharmaceuticals, Inc.
11682 El Camino Real
Suite 120
San Diego, CA 92130
Re:ARS Pharmaceuticals, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2023
File No. 001-39756
Dear Kathleen Scott:
We have completed our review of your filing. We remind you that the company and
its management are responsible for the accuracy and adequacy of their disclosures,
notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences